In the past week, MREO stock has gone up by 5.15%, with a monthly gain of 16.57% and a quarterly surge of 46.76%. The volatility ratio for the week is 6.25%, and the volatility levels for the last 30 days are 6.48% for Mereo Biopharma Group Plc ADR The simple moving average for the last 20 days is 7.16% for MREO stock, with a simple moving average of 37.90% for the last 200 days.
Is It Worth Investing in Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Right Now?
Additionally, the 36-month beta value for MREO is 0.88. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MREO is 140.27M and currently, short sellers hold a 2.23% ratio of that float. The average trading volume of MREO on July 26, 2024 was 1.07M shares.
MREO) stock’s latest price update
The stock of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) has increased by 3.29 when compared to last closing price of 3.95. Despite this, the company has experienced a 5.15% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-06-14 that LONDON, June 14, 2024 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. Each ADS represents five ordinary shares of Mereo. The net proceeds of this offering are expected to be used to fund the setrusumab program, including supply and pre-launch activities in Europe, and for working capital and other general corporate purposes. The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions.
Analysts’ Opinion of MREO
Many brokerage firms have already submitted their reports for MREO stocks, with Robert W. Baird repeating the rating for MREO by listing it as a “Outperform.” The predicted price for MREO in the upcoming period, according to Robert W. Baird is $8 based on the research report published on June 13, 2024 of the current year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see MREO reach a price target of $4. The rating they have provided for MREO stocks is “Buy” according to the report published on October 13th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to MREO, setting the target price at $4 in the report published on August 12th of the previous year.
MREO Trading at 13.19% from the 50-Day Moving Average
After a stumble in the market that brought MREO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.33% of loss for the given period.
Volatility was left at 6.48%, however, over the last 30 days, the volatility rate increased by 6.25%, as shares surge +16.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.37% upper at present.
During the last 5 trading sessions, MREO rose by +5.15%, which changed the moving average for the period of 200-days by +218.75% in comparison to the 20-day moving average, which settled at $3.84. In addition, Mereo Biopharma Group Plc ADR saw 76.62% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MREO starting from Scots-Knight Denise, who sale 92,273 shares at the price of $3.39 back on Jun 26 ’24. After this action, Scots-Knight Denise now owns 709,518 shares of Mereo Biopharma Group Plc ADR, valued at $313,101 using the latest closing price.
Sermon Charles, the General Counsel of Mereo Biopharma Group Plc ADR, sale 32,187 shares at $3.39 during a trade that took place back on Jun 26 ’24, which means that Sermon Charles is holding 184,387 shares at $109,217 based on the most recent closing price.
Stock Fundamentals for MREO
Current profitability levels for the company are sitting at:
- -3.87 for the present operating margin
- 0.57 for the gross margin
The net margin for Mereo Biopharma Group Plc ADR stands at -3.63. The total capital return value is set at -0.83. Equity return is now at value -39.59, with -26.75 for asset returns.
Based on Mereo Biopharma Group Plc ADR (MREO), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -4.87. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is 11.75.
Currently, EBITDA for the company is -23.95 million with net debt to EBITDA at 1.16. When we switch over and look at the enterprise to sales, we see a ratio of 57.38. The receivables turnover for the company is 4.5for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.86.
Conclusion
In conclusion, Mereo Biopharma Group Plc ADR (MREO) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
